Toripalimab combined with definitive chemoradiotherapy for locally advanced cervical squamous cell carcinoma patients (TRACE): A single-arm, phase I/II trial
Toripalimab combined with CCRT achieved good tolerance and showed promising anti-tumor effects in patients with locally advanced cervical cancer.
Authors
- Can Cui (ORCID: https://orcid.org/0000-0003-1139-0182)
- Ying Miao (ORCID: https://orcid.org/0000-0003-2220-455X)
- Gang Cai (ORCID: https://orcid.org/0000-0001-5465-7532)
- Rong Cai (ORCID: https://orcid.org/0000-0001-6793-5765)
- Weiguo Cao (ORCID: https://orcid.org/0000-0002-6482-2877)
- Huan Li (ORCID: https://orcid.org/0000-0001-8568-3151)
- Jiayi Chen (ORCID: https://orcid.org/0000-0001-6417-290X)
- Haoping Xu
- Cheng Xu (ORCID: https://orcid.org/0000-0002-4062-3558)
- Wei-Xiang Qi
- Dan Ou (ORCID: https://orcid.org/0000-0001-6427-4199)
- Tao Ma (ORCID: https://orcid.org/0009-0003-4036-1476)
- Shu-Bei Wang
- Gao Yun-sheng
- Lu Cao
Institutions
- John H. Stroger, Jr. Hospital of Cook County (US)
- Ruijin Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1007/s00262-024-03823-1
- Citations
- 4
- Primary Topic
- Colorectal and Anal Carcinomas
- Type
- article
- Field-Weighted Citation Impact
- 2.29